Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Clinical Lung Cancer|July 6, 2011
Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based reviewAlex A Adjei, George R Blumenschein, Sumithra Mandrekar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2010
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment studyMartin Reck, Nico van Zandwijk, Cesare Gridelli, et al.
Lung Cancer (Amsterdam, Netherlands)|December 14, 2011
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancerMark J C Nuijten, Javier de Castro Carpeño, Christos Chouaid, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 26, 2012
Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancerSylvia K Haas, Mathias Freund, David Heigener, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 3, 2012
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across EuropeSilke Walleser, Joshua Ray, Helge Bischoff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 6, 2008
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST studyClaus-Peter Schneider, David Heigener, Kathrin Schott-von-Römer, et al.
Lung Cancer (Amsterdam, Netherlands)|March 2, 2010
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation studyMartin Reck, Norbert Frickhofen, Susana Cedres, et al.
Digital Health|July 18, 2025
Feasibility of evaluating AI-enabled digital symptom monitoring in metastatic patients with NSCLC receiving pembrolizumab therapy: A German single-arm observational pilot studyMelissa L Santorelli, Oliver Schmalz, Mathias Hoiczyk, et al.
Molecular Oncology|March 9, 2023
Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patientsMustafa Abdo, Yassine Belloum, David Heigener, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 3, 2008
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access ProgramPaul Taylor, Bruno Castagneto, Graham Dark, et al.
Pageof 3